BTIG lowered the firm’s price target on Staar Surgical (STAA) to $39 from $49 and keeps a Buy rating on the shares as part of ...

STAAR Surgical (NASDAQ:STAA) rose 6.5% amid some takeover speculation. The maker of implantable lenses is said to have been ...

BTIG analyst Ryan Zimmerman maintained a Buy rating on Staar Surgical (STAA – Research Report) today and set a price target of $39.00. The ...

Update 3:35pm: Updates shares, adds STAAR surgical response. "We are very pleased with our momentum in 2024 and will provide an update on our performance on our 2Q earnings call in early August ...

LAKE FOREST, Calif., November 25, 2024--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for ...

Stephan covers the Healthcare sector, focusing on stocks such as Glaukos, Staar Surgical, and Alcon. Glaukos has an analyst consensus of Strong Buy, with a price target consensus of $154.00, ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

What is the current share price of STAAR Surgical Company (STAA)? STAAR Surgical Company's (STAA) current share price is $27.72. This constitutes a price movement of 3.90% when compared to the share ...

STAAR Surgical Co. engages in the design, development, manufacture, and sale of ophthalmic surgical products. The firm offers implantable lenses for the eye and accessory delivery systems.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Nasdaq provides visual representation of analyst expected earnings growth. Read our earnings report guide before you consider the forecast information when making investment decisions. Visit the ...